SG10201510586PA - Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy - Google Patents

Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy

Info

Publication number
SG10201510586PA
SG10201510586PA SG10201510586PA SG10201510586PA SG10201510586PA SG 10201510586P A SG10201510586P A SG 10201510586PA SG 10201510586P A SG10201510586P A SG 10201510586PA SG 10201510586P A SG10201510586P A SG 10201510586PA SG 10201510586P A SG10201510586P A SG 10201510586PA
Authority
SG
Singapore
Prior art keywords
treatment
eye diseases
combined therapy
excessive neovascularization
neovascularization
Prior art date
Application number
SG10201510586PA
Inventor
Michael David Schuster
Silviu Itescu
Original Assignee
Mesoblast Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008903349A external-priority patent/AU2008903349A0/en
Application filed by Mesoblast Inc filed Critical Mesoblast Inc
Publication of SG10201510586PA publication Critical patent/SG10201510586PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
SG10201510586PA 2008-06-30 2009-06-29 Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy SG10201510586PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13360708P 2008-06-30 2008-06-30
AU2008903349A AU2008903349A0 (en) 2008-06-30 Treatment of eye diseases and excessive neovascularization using combined therapy

Publications (1)

Publication Number Publication Date
SG10201510586PA true SG10201510586PA (en) 2016-01-28

Family

ID=41507350

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201510586PA SG10201510586PA (en) 2008-06-30 2009-06-29 Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy

Country Status (9)

Country Link
US (1) US20110200612A1 (en)
EP (1) EP2294184A4 (en)
JP (2) JP2011526892A (en)
KR (1) KR20110036101A (en)
CN (1) CN102076844B (en)
AU (2) AU2009269149B2 (en)
CA (1) CA2729303A1 (en)
SG (1) SG10201510586PA (en)
WO (1) WO2010005527A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US8915253B2 (en) 2005-07-18 2014-12-23 Tearscience, Inc. Method and apparatus for treating gland dysfunction employing heated medium
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
WO2012048275A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
CN110051693A (en) * 2011-07-04 2019-07-26 麦瑟布莱斯特公司 The method for treating or preventing rheumatic disease
HUE039236T2 (en) 2011-07-06 2018-12-28 Cell Therapy Ltd Progenitor cells of mesodermal lineage
FR2983478B1 (en) 2011-12-01 2013-11-15 Arkema France PROCESS FOR PREPARING AMINOACID COMPRISING A HYDROFORMYLATION STEP OF UNSATURATED FATTY NITRILE
CN103505727A (en) * 2012-06-28 2014-01-15 中国科学院生物物理研究所 Application of novel function of CD146 targeted as co-receptor of vascular endothelial growth factor receptor-2 (VEGFR-2) in anti-tumor angiogenesis treatment
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
EP2890389A1 (en) * 2012-08-28 2015-07-08 Novartis AG Use of a vegf antagonist in treating ocular vascular proliferative diseases
US20160175360A1 (en) * 2012-12-12 2016-06-23 Mesoblast, Inc. Treatment of diseases of endothelial dysfunction and inflammation
EP3744391B1 (en) 2013-04-30 2023-03-01 Alcon Inc. Systems for the treatment of eye conditions
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
JP6633522B2 (en) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド Cell growth in bioreactors
ES2851386T3 (en) * 2013-12-18 2021-09-06 Csl Ltd Wound treatment method
WO2015148704A1 (en) 2014-03-25 2015-10-01 Terumo Bct, Inc. Passive replacement of media
JP6830059B2 (en) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド Scheduled cell feeding
KR101880790B1 (en) * 2015-04-07 2018-08-16 서강대학교산학협력단 Nanoparticles for genes drug delivery with siRNA for the long -term treatment of retinal disorders and method for preparing the same
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
US20170253854A1 (en) * 2016-03-02 2017-09-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of Adipose-Derived Stem Cells for Glaucoma Treatment
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
US11279935B2 (en) 2016-07-08 2022-03-22 Tak-Circulator Co, Ltd Method for screening prophylactic or therapeutic agents for diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5
US11312956B2 (en) 2016-07-08 2022-04-26 Tak-Circulator Co., Ltd Nucleic acid inhibiting expression of the MEX3B gene, MEX3B gene expression inhibitor, method for inhibiting MEX3B gene expression, and prophylactic or therapeutic agent for disease caused by MEX3B gene expression
WO2018022683A1 (en) * 2016-07-26 2018-02-01 The University Of North Carolina At Chapel Hill Vector-mediated immune tolerance in the eye
US11401502B2 (en) 2016-11-15 2022-08-02 Kaneka Corporation Cell population comprising mesenchymal stem cells derived from fetal appendage, method for producing the same, and pharmaceutical composition
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
CN107043699B (en) * 2017-04-25 2023-04-07 徐子雁 Kit for inducing vascularization of mesenchymal stem cells by low-energy laser
WO2019005737A1 (en) * 2017-06-26 2019-01-03 Amd-Opti, Llc Autologous stem cell therapies for treatment of eye disease
EP3750987A4 (en) 2017-12-28 2021-11-10 Kaneka Corporation Cell population including adhesive stem cells, production method therefor, and pharmaceutical composition
US20220079991A1 (en) * 2019-01-03 2022-03-17 Mesoblast International Sárl Method for improving visual acuity
CN113993527A (en) 2019-06-14 2022-01-28 株式会社钟化 Cell population comprising mesenchymal cells, pharmaceutical composition comprising the same, and method for producing the same

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3089815A (en) 1951-10-11 1963-05-14 Lieb Hans Injectable pharmaceutical preparation, and a method of making same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4983393A (en) 1987-07-21 1991-01-08 Maximed Corporation Intra-vaginal device and method for sustained drug release
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
JP4124480B2 (en) 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド Immunoglobulin variants
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
EP0748215B1 (en) 1994-02-17 2003-05-28 New York Blood Center, Inc. Biologic bioadhesive compositions containing fibrin glue and liposomes, methods of preparation and use
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US5643192A (en) 1995-04-06 1997-07-01 Hamilton Civic Hospitals Research Development, Inc. Autologous fibrin glue and methods for its preparation and use
US5730977A (en) 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US20030216335A1 (en) 2001-11-30 2003-11-20 Jennifer Lockridge Method and reagent for the modulation of female reproductive diseases and conditions
DE19638745C2 (en) 1996-09-11 2001-05-10 Schering Ag Monoclonal antibodies against the extracellular domain of the human VEGF receptor protein (KDR)
JP2001500890A (en) 1996-09-25 2001-01-23 ゼネカ リミテッド Quinoline derivatives that inhibit the action of growth factors such as VEGF
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6986890B1 (en) 1996-11-21 2006-01-17 Kyowa Hakko Kogyo Co., Ltd. Anti-human VEGF receptor Flt-1 monoclonal antibody
US6162428A (en) 1997-02-12 2000-12-19 Layton Bioscience, Inc. hNT-neuron human neuronal cells to replace ganglion cells
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU2299099A (en) 1998-02-04 1999-08-23 Kyowa Hakko Kogyo Co. Ltd. Antibodies against human vegf receptor kdr
CA2487328A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd. Sirna for control of gene expression
CN1202246C (en) 1998-04-08 2005-05-18 联邦科学和工业研究组织 Methods for means for obtaining modified phenotypes
US6284245B1 (en) 1998-08-25 2001-09-04 Diacrin, Inc. Neural retinal cells and retinal pigment epithelium cells and their use in treatment of retinal disorders
JP4632543B2 (en) 1998-12-21 2011-02-16 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Cleaved VEGF-D antibody and use thereof
WO2001002344A1 (en) 1999-07-01 2001-01-11 Taisho Pharmaceutical Co., Ltd. Aminobenzoic acid derivatives
AUPQ147799A0 (en) 1999-07-07 1999-07-29 Medvet Science Pty. Ltd. Mesenchymal precursor cell
AU2003901668A0 (en) * 2003-03-28 2003-05-01 Medvet Science Pty. Ltd. Non-haemopoietic precursor cells
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US7173038B1 (en) 1999-11-05 2007-02-06 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
DE69930150T2 (en) 1999-12-21 2006-11-30 Korea Green Cross Corp., Yongin ARGININE-RICH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PEPTIDES INHIBITING GROWTH AND METASTASE HUMAN TUMOR CELLS THROUGH BLOCKING OF THE ANGIOGENESIS
US7045133B2 (en) 2000-01-18 2006-05-16 Ludwig Institute For Cancer Research VEGF-D/VEGF-C/VEGF peptidomimetic inhibitor
WO2001057067A1 (en) 2000-02-04 2001-08-09 Supratek Pharma Inc. Ligand for vascular endothelial growth factor receptor
ATE295365T1 (en) 2000-02-09 2005-05-15 Novartis Pharma Gmbh PYRIDINE DERIVATIVES AS ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE INHIBITORS
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
WO2001060814A2 (en) 2000-02-15 2001-08-23 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
EP1268544A2 (en) 2000-03-31 2003-01-02 Institut Pasteur Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
JP2004513676A (en) 2000-06-22 2004-05-13 オースティン，サム，エル Bioadhesive composition and its production and use
AU2001276536B2 (en) 2000-08-09 2007-01-04 Astrazeneca Ab Quinoline derivatives having vegf inhibiting activity
AU2002210295A1 (en) 2000-10-13 2002-04-22 Institut De Cardiologie De Montreal Antisense oligonucleotide directed toward mammalian vegf receptor genes and uses thereof
JP2004517631A (en) 2001-01-17 2004-06-17 ヨウン メー パク Method for inhibiting gene expression of vascular endothelial growth factor and erythropoietin by quercetin
AU2002338313A1 (en) 2001-04-06 2002-10-21 Maxygen Holdings Ltd. Single chain dimeric polypeptides derived from the vegf family
CA2444624A1 (en) 2001-04-13 2002-10-24 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US20050222066A1 (en) 2001-05-18 2005-10-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050148530A1 (en) 2002-02-20 2005-07-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050054596A1 (en) 2001-11-30 2005-03-10 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
WO2003070910A2 (en) 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated INHIBITION OF VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND VEGF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2003027247A2 (en) * 2001-09-24 2003-04-03 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
US6942655B2 (en) 2001-11-13 2005-09-13 Minu, Llc Method to treat age-related macular degeneration
US20040138163A1 (en) 2002-05-29 2004-07-15 Mcswiggen James RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7378246B2 (en) * 2002-02-28 2008-05-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for regulating adipogenesis
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US20040121955A1 (en) 2002-04-01 2004-06-24 Mulligan-Kehoe Mary Jo Methods for modulating angiogenesis
CA2429483A1 (en) 2002-05-17 2003-11-17 Amrad Operations Pty Ltd. Immunointeractive molecules
CN1720055A (en) 2002-10-04 2006-01-11 组织技术公司 Retinal pigment epithelial cell cultures on amniotic membrane and transplantation
CA2407755A1 (en) * 2002-10-11 2004-04-11 The Hospital For Sick Children Inhibition of vegf secretion
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
MXPA05009303A (en) 2003-04-03 2005-10-05 Pfizer Dosage forms comprising ag013736.
US20040198798A1 (en) 2003-04-07 2004-10-07 Park Jong-Wan Method for inhibiting tumor angiogenesis and tumor growth
US20050049309A1 (en) 2003-07-14 2005-03-03 Lynn Kirkpatrick Regulation of HIF protein levels via deubiquitination pathway
AR046510A1 (en) 2003-07-25 2005-12-14 Regeneron Pharma COMPOSITION OF A VEGF ANTAGONIST AND AN ANTI-PROLIFERATIVE AGENT
GB0318423D0 (en) 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
WO2005034881A2 (en) * 2003-10-10 2005-04-21 Beth Israel Deaconess Medical Center Methods and compositions for treating conditions involving abnormal angiogenesis
GB0328021D0 (en) 2003-12-03 2004-01-07 Inst Of Ophthalmology Method
EP2365077B1 (en) 2004-03-12 2013-05-08 Alnylam Pharmaceuticals, Inc. iRNA agents targeting VEGF
EP2471924A1 (en) * 2004-05-28 2012-07-04 Asuragen, INC. Methods and compositions involving microRNA
US7150970B2 (en) 2004-08-02 2006-12-19 University Of Iowa Research Foundation Methods of inhibiting VEGF-C
EP1786477A2 (en) * 2004-08-17 2007-05-23 Prolx Pharmaceuticals Corp. Method of preselection patients for anti-vegf, anti-hif-1 or anti-thioredoxin therapy
US20060110364A1 (en) 2004-08-20 2006-05-25 Ludwig Institute For Cancer Research Vector-mediated delivery of polynucleotides encoding soluble VEGF receptors
JP5265190B2 (en) 2004-09-24 2013-08-14 メソブラスト，インコーポレーテッド Pluripotent proliferating mesenchymal progenitor progeny (MEMP) and uses thereof
US7947267B2 (en) * 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
CN101083998A (en) * 2004-11-22 2007-12-05 王者制药研究发展有限公司 Enhancing treatment of hif-1 mediated disorders with adenosine a3 receptor agonists
AU2006229687B2 (en) * 2005-02-24 2011-08-11 The Scripps Research Institute Isolated myeloid-like bone marrow cell populations and methods of treatment therewith
US20070231306A1 (en) * 2005-02-24 2007-10-04 The Scripps Research Institute Isolated myeloid-like cell populations and methods of treatment therewith
KR101617319B1 (en) 2005-04-12 2016-05-02 메소블라스트, 아이엔씨. Isolation of adult multipotential cells by tissue non-specific alkaline phosphatase
US20060234941A1 (en) 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
WO2007013704A1 (en) 2005-07-27 2007-02-01 Juseong College Industry Academy Cooperation Group Recombinant adeno-associated virus comprising antisense cdnas of vegf-a, vegf-b and vegf-c and gene therapeutic agent specific to large intestine cancer, bladder cancer and/or lung cancer comprising the same
CA2627873A1 (en) 2005-10-31 2007-05-10 Scott Wilhelm Treatment of cancer with sorafenib
GB0523810D0 (en) 2005-11-23 2006-01-04 Astrazeneca Ab Pharmaceutical compositions
CN100371444C (en) 2005-12-12 2008-02-27 清华大学深圳研究生院 VEGF expression-inhibiting siRNA and application thereof
CN100374573C (en) 2006-04-14 2008-03-12 中国医学科学院医药生物技术研究所 Carrier PCD-VEGF able to stable express VEGF shRNA
US20080089868A1 (en) 2006-04-27 2008-04-17 The Research Foundation Of State University Of New York Retinal stem cell compositions and methods for preparing and using same
WO2007130060A2 (en) 2006-05-03 2007-11-15 Schepens Eye Research Isolation and therapeutic application of adult retinal stem cells collected from extra-retinal tissues
WO2007136673A2 (en) * 2006-05-19 2007-11-29 Medistem Laboratories, Inc. Treatment of disc degenerative disease and compositions for same
WO2007140534A1 (en) 2006-06-08 2007-12-13 Csl Limited Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
KR100787131B1 (en) 2006-07-04 2007-12-21 한국생명공학연구원 Compounds that inhibit hif-1 activity the method for preparation thereof and the pharmaceutical composition containing them as an effective component
JP6041456B2 (en) * 2006-07-12 2016-12-07 メゾブラスト，インコーポレーテッド Treatment of excessive neovascularization
CA2658972C (en) * 2006-07-31 2019-11-26 Vascular Biogenics Ltd. Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia
WO2008031835A2 (en) 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors
WO2008045576A2 (en) 2006-10-12 2008-04-17 Yijia Liu Compositions and methods of rnai therapeutics for treatment of cancer and other neovascularization diseases
US8277807B2 (en) * 2006-10-12 2012-10-02 Astex Therapeutics Limited Pharmaceutical combinations
WO2008063932A2 (en) * 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
EP2114327A1 (en) * 2007-02-14 2009-11-11 Opto Global Holdings Pty Ltd. Methods and systems of treating age-related macular degeneration
US8983570B2 (en) * 2007-03-27 2015-03-17 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treatment of the spine
US7867724B2 (en) * 2007-11-05 2011-01-11 California Institute Of Technology Compositions and method of treating hypoxia-associated diseases
WO2009114623A2 (en) * 2008-03-11 2009-09-17 University Of North Carolina At Chapel Hill Angiostatic compositions comprising truncated tyrosyl-trna synthetase polypeptides and methods of using same
WO2010068794A2 (en) * 2008-12-10 2010-06-17 The General Hospital Corporation Hif inhibitors and use thereof
BR112013000341A2 (en) * 2010-07-07 2017-09-26 Tubitak recombinant antibody structures by binding and blocking growth of factor 2 endothelial vascular activity (vegfr-2 / kdr)

Also Published As

Publication number Publication date
EP2294184A1 (en) 2011-03-16
AU2009269149A1 (en) 2010-01-14
US20110200612A1 (en) 2011-08-18
JP2011526892A (en) 2011-10-20
CA2729303A1 (en) 2010-01-14
CN102076844B (en) 2013-08-07
JP2015038059A (en) 2015-02-26
EP2294184A4 (en) 2013-03-06
KR20110036101A (en) 2011-04-06
WO2010005527A1 (en) 2010-01-14
AU2009269149B2 (en) 2016-03-17
CN102076844A (en) 2011-05-25
AU2016203973A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
SG10201510586PA (en) Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy
IL242268A0 (en) Combinations and modes of administration of therapeutic agents and combination therapy
ZA201106268B (en) Toll-like receptor modulators and treatment of diseases
HK1201046A1 (en) Methods of treating ophthalmic diseases
IL207014A0 (en) Enhanced delivery of a therapeutic to ocular tissues through iontophoresis
IL229786A (en) Use of inhibitors for preparation of medicaments for treating ocular edema, neovascularization and related diseases
ZA201106730B (en) Methods of treatment using combination therapy
EP2182983A4 (en) Treatment of amyloidogenic diseases
HK1173654A1 (en) Therapeutic compounds and related methods of use
EP2046349A4 (en) Treatment of excessive neovascularization
ZA200906165B (en) Treatment and prevention of neurodegenerative diseases using gene therapy
HK1243436A1 (en) Therapeutic use of specific ligand in msrv associated diseases
EP2624821A4 (en) Combination therapy for the treatment of depression and other non-infectious diseases
EP2710017A4 (en) Macrocycllc therapeutic agents and methods of treatment
IL214291A (en) Use of deferiprone for preparation of a medicament for treatment and prevention of iron-related eye disorders
AU2008903349A0 (en) Treatment of eye diseases and excessive neovascularization using combined therapy
GB201108289D0 (en) Therapeutic garment and method of providing therapy using the same
GB0801511D0 (en) The treatment of ophthalmic diseases
IL231052B (en) Bacteriochlorophyll photosensitizers for treatment of eye diseases and disorders
GB0901727D0 (en) The treatment of ophthalmic diseases
GB0724970D0 (en) Treatment and prevention of nuerodegenerative diseases
ZA200906883B (en) Methods of treating ophthalmic diseases
GB0700755D0 (en) The Treatment of ophthalmic diseases
GB0920424D0 (en) Therapeutic vaccine for treatment of type 2-diabetes and impaired glucose tolerance
GB0920200D0 (en) Therapeutic vaccine for treatment of type 2-diabetes and impaired glucose tolerance